Axitinib Improves Radiotherapy in Murine Xenograft Lung Tumors  by Hillman, Gilda G. et al.
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 3 June 2014 pp. 400–409 400Axitinib Improves Radiotherapy
in Murine Xenograft
Lung TumorsGilda G. Hillman*, Fulvio Lonardo†,
David J. Hoogstra*, Joseph Rakowski*,
Christopher K. Yunker*, Michael C. Joiner*,
Gregory Dyson‡,§, Shirish Gadgeel§
and Vinita Singh-Gupta*
*Department of Radiation Oncology, Barbara Ann Karmanos
Cancer Institute, Wayne State University School of
Medicine, Detroit, MI 48201, USA; †Department of
Pathology, Barbara Ann Karmanos Cancer Institute, Wayne
State University School of Medicine, Detroit, MI 48201,
USA; ‡Department of Biostatistics Core, Barbara Ann
Karmanos Cancer Institute, Wayne State University School
of Medicine, Detroit, MI 48201, USA; §Department of
Oncology, Barbara Ann Karmanos Cancer Institute, Wayne
State University School of Medicine, Detroit, MI 48201, USAAbstract
A third of patients with non-small cell lung cancer (NSCLC) present with un-resectable stage III locally advanced
disease and are currently treated by chemo-radiotherapy but the median survival is only about 21 months. Using
an orthotopic xenograft model of lung carcinoma, we have investigated the combination of radiotherapy with the
anti-angiogenic drug axitinib (AG-013736, Pfizer), which is a small molecule receptor tyrosine kinase inhibitor that
selectively targets the signal transduction induced by VEGF binding to VEGFR receptors. We have tested the
combination of axitinib with radiotherapy in nude mice bearing human NSCLC A549 lung tumors. The therapy
effect was quantitatively evaluated in lung tumor nodules. The modulation of radiation-induced pneumonitis,
vascular damage and fibrosis by axitinib was assessed in lung tissue. Lung irradiation combined with long-term
axitinib treatment was safe resulting in minimal weight loss and no vascular injury in heart, liver and kidney
tissues. A significant decrease in the size of lung tumor nodules was observed with either axitinib or radiation,
associated with a decrease in Ki-67 staining and a heavy infiltration of inflammatory cells in tumor nodules. The
lungs of mice treated with radiation and axitinib showed a complete response with no detectable residual tumor
nodules. A decrease in pneumonitis, vascular damage and fibrosis were observed in lung tissues from mice
treated with radiation and axitinib. Our studies suggest that axitinib is a potent and safe drug to use in
conjunction with radiotherapy for lung cancer that could also act as a radioprotector for lung tissue by reducing
pneumonitis and fibrosis.
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Lung cancer is the second most common malignancy in both men
and women in the USA and the leading cause of death. It is estimated
that over 215,000 people per year will be diagnosed with lung cancer
[1]. Approximately 85% of lung cancers are classified as non-small
cell lung cancer (NSCLC), which includes squamous cell carcinoma,
adenocarcinoma and large cell carcinoma. A third of patients with
newly diagnosed NSCLC present with unresectable stage IIIA or stage
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16% [2]. Locally advanced disease is currently treated by chemo-
radiotherapy [3–5]. Several trials showed that concurrent cisplatin
chemotherapy with radiotherapy (RT) is superior to sequential
chemotherapy followed by RT or to RT alone; however the median
survival is only about 21 months [4]. Biological agents are currently
being tested to improve the outcome of chemo-RT for locally
advanced NSCLC including anti-angiogenic drugs and cetuximab, an
anti-EGFR antibody (Ab) [6]. Bevacizumab, an anti-VEGF
monoclonal Ab that acts as an anti-angiogenic drug, showed modest
benefit when used in combination with first line carboplatin-
paclitaxel or cisplatin and gemcitabine chemotherapy in patients with
non-squamous advanced NSCLC [7,8]. Because bevacizumab has a
prolonged half-life, which allows administration every 2-3 weeks,
toxicity and bleeding are of concern [7]. Bevacizumab significantly
increased the risk of grade ≥3 proteinuria, hypertension, haemor-
rhagic events, neutropenia and febrile neutropenia compared to
chemotherapy alone [9]. Bevacizumab given with concurrent thoracic
radiotherapy for stage III NSCLC also resulted in severe pneumonitis
in a recent phase I clinical trial [10] and increased esophagitis in other
trials with radiotherapy [11,12]. Novel anti-angiogenic drugs with
shorter half-life than bevacizumab, and that could be less toxic,
include small molecule receptor tyrosine kinase (RTKs) inhibitors
target VEGF receptors (VEGFR) and inhibit the signal transduction
induced by VEGF binding to VEGFR. These drugs are administered
daily because of their short-half-life [13]. Among others, sunitinib, a
multiple RTK inhibitor, has shown efficacy in metastatic renal cell
carcinoma but has dose-limiting toxicity [13]. Sunitinib had limited
efficacy in NSCLC and is currently tested in clinical trials in
combination with chemotherapy [14,15]. Axitinib (AG-013736,
Pfizer) is a more selective RTK inhibitor of all three VEGF receptors
VEGFR-1, -2 and -3 than sunitinib [16]. Axitinib has a high potency
for VEGFR-2, the main receptor involved in VEGF binding that is
critical for induction of angiogenesis and therefore could target the
tumor sites more specifically [16,17]. Axitinib has proven to be a very
potent inhibitor of VEGFR-2 signaling in pre-clinical studies [18–21].
Advantages of axitinib over other anti-angiogenic drugs are that it has a
favorable profile of toxicity with the absence of cumulative dose-limiting
toxicity and it can be given in a constant and manageable schedule of
administration [16]. This drug has a shorter half-life (2-5 h) than
bevacizumab and its daily administration could be better controlled to
limit toxicity [22]. Axitinib used in a phase II trial for advancedNSCLC
demonstrated an increased one-year survival rate with manageable
toxicities [17,22] and was well tolerated when combined with platinum
doublets chemotherapy [23]. The role of angiogenesis in the progression
and prognosis of NSCLC and its targeting by various new anti-
angiogenic drugs either alone or combined with conventional
chemotherapy for NSCLC are under extensive clinical investigation
[24–27]. However, the combination of anti-angiogenic drugs with RT,
which is the conventional treatment for stage III inoperable NSCLC,
has not been explored.
The goal of the current study was to explore whether axitinib could
improve the efficacy of RT for NSCLC using a pre-clinical model of
orthotopic lung carcinoma. We hypothesized that an anti-angiogenic
drug, given at doses which trim inefficient tumor vessels and
regularize blood flow, could improve oxygenation in the tumor
microenvironment and enhance RT efficacy for locally advanced
NSCLC. Alternatively, higher doses of anti-angiogenic drugs
resulting in a cytostatic effect could enhance the cytoreductive effectof RT. Using these concepts, we have previously demonstrated that a
dose of sunitinib, which regularized tumor vessels and blood flow,
enhanced the efficacy of chemo- and radio-therapies for metastatic
RCC in an orthotopic RCC pre-clinical mode [28–30]. However, the
dose of sunitinib used in these studies was reduced to avoid toxicity to
the vasculature of normal tissues [28–30]. We now report studies
confirming that axitinib is a potent and safe anti-angiogenic drug that
significantly enhances the efficacy of lung irradiation in an orthotopic
xenograft model of lung carcinoma. This combined therapy is well
tolerated with no further increase in radiation-induced injury or
vascular damage in lung tissue but quite the opposite effect was
observed suggesting a radioprotective effect.
Materials and Methods
Establishment of NSCLC Lung Tumor Model
The human non-small cell lung carcinoma (NSCLC) A549
(purchased from ATCC) was cultured in F-12 K culture medium
containing 7% heat-inactivated fetal bovine serum with supplements.
A549 cells, at 2x10 [6] in 200 μl HBSS, were injected i.v. in the tail
vein of 5-6 week old female Hsd Athymic Nude-Foxn1nu nu/nu nude
mice (Harlan, Indianapolis, IN) [31]. Mice were housed and handled
under sterile conditions in facilities accredited by the American
Association for the Accreditation of Laboratory Animal Care
(AAALAC). The animal protocol was approved by Wayne State
University Animal Investigation Committee (IACUC).
Tumor-bearing lung irradiation
Three anesthetized mice, in jigs, were positioned under a 6.4 mm
lead shield with 3 cut-outs in an aluminum framemounted on the X-ray
machine to permit selective irradiation of tumor-bearing lungs in the
thoracic area, as previously described [31]. The radiation dose to the
lung and the scattered dose to areas of themouse outside of the radiation
field were carefully monitored. Photon irradiation was performed at a
dose of 10 Gy with a Siemens Stabilipan X-ray set (Siemens Medical
Systems, Inc) operated at 250 kV, 15 mA with 1 mm copper filtration
at a distance of 47.5 cm from the target. A high dose of radiation of
10 Gy was selected for these studies with the rationale that such a dose
could inflict greater damage to normal lung tissue and will allow for
evaluation of potential injury aggravation by axitinib.
Experimental protocol
Axitinib (Pfizer Inc, New York, NY), was prepared in a
carboxymethyl cellulose suspension vehicle, and given orally by
gavage at a dose of 25 mg/kg (0.5 mg/mouse) per day, once a day.
The dose was selected to give an intermediate effect for combination
with radiation, based on previous titration studies [20]. As previously
reported, to monitor tumor establishment in the lungs of mice,
preliminary kinetics experiments were performed and mice were
sacrificed at different time points after i.v. injection of A549 cells
[31,32]. Lungs were resected and processed for histological staining
with hematoxylin-eosin (H&E). Established tumor nodules of about
100-300 μm in diameter were detected by day 17-18 in the midst of
the lung tissue, therefore this time point was selected to initiate
treatment with axitinib. Tumor bearing mice were pre-treated with
axitinib for 4 days from day 17-20 (Table 1A). Then, on day 21, the
full lung was selectively irradiated by delivering 10 Gy to the thorax
while shielding the rest of the mouse body with lead. Axitinib
treatment was resumed at 25 mg/kg/day and given 5 days a week for
5 more weeks (Table 1A). At this time point, axitinib was
Table 1. Axitinib combined with radiation in mice-bearing A549 lung tumors.
A. Treatment Schedule
B. Effect of therapy on mouse weight
Mouse weight (mean ± SE in gm)
Treatment Day 25 Day 36 Day 46 Day 53 Day 67 Day 79
Control 23.1 ± 0.4 24.0 ± 0.4 24.7 ± 0.4 24.3 ± 0.5 25.4 ± 0.6 26.6 ± 0.7
Axitinib
(10 Weeks)
22.0 ± 0.5 22.3 ± 0.5 23.2 ± 0.6 22.4 ± 0.9 23.8 ± 0.9 24.7 ± 1.1
Axitinib
(5 weeks)
N/A N/A N/A 23.4 ± 0.5 23.7 ± 0.9 25.5 ± 1.0
Rad 21.4 ± 0.3 22.4 ± 0.7 23.3 ± 0.3 24.2 ± 0.3 25.1 ± 0.3 24.7 ± 0.8
Rad + Axitinib
(10 weeks)
21.9 ± 0.7 23.0 ± 0.6 23.5 ± 0.6 22.6 ± 1.0 23.4 ± 1.2 24.3 ± 1.4
Rad + Axitinib
(5 weeks)
N/A N/A N/A 24.4 ± 0.6 25.3 ± 0.8 26.5 ± 0.7
A.Treatment schedule:Mice bearing A549 lung tumors were pre-treatedwith axitinib at 25 mg/kg/day
for 4 days, on days 17-20 after i.v. A549 cell injection. Then, mice received 10 Gy radiation to the
tumor-bearing lungs on day 21. Axitinib was continued 5 days a week for up to 5 weeks (day 49). In
treatment groups of mice receiving axitinib alone or axitinib + radiation, axitinib was discontinued in
half of the mice whereas the other half of the mice received 5 more weeks of axitinib. Mice were
monitored for about 3 months and killed on day 88.
B.Mouse weight:Mice bearing A549 lung nodules treated with Axitinib for 4 days then with 10 Gy radiation to
the whole lung. After radiation, axitinib was given for 10 weeks or was discontinued after 5 weeks.
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received 5 more weeks of axitinib. The number of mice per treatment
group was 8 in control, 8 in axitinib, 9 in radiation and 9 in
radiation + axitinib. To assess the therapeutic response of lung
tumors to axitinib and radiation, mouse survival was monitored in a
long-term experiment of about 3 months. Mice exhibiting weight
loss, lethargy or gross metastases in the limbs were killed and lungs
were perfused with 10% buffered formalin prior to resection.
Histology of lung tissue sections
Formalin fixed lungs were embedded in paraffin and sectioned into
5 μm sections. Sections were stained with (H&E). Quantitation of
histological findings was performed by evaluation of lung tissues using
a Nikon E-800 microscope. The number of nodules in the five lobes
of the mouse lungs was enumerated. Morphometric measurements of
each tumor nodule were performed using Image-ProPlus version 6.2
software (MediaCybernetics) [31]. The two largest diameters of each
nodule were measured and computed to estimate the nodule surface
area. The same software was used to measure the thickness of alveolar
septa on H&E slides as an estimate of pneumonitis. The ratio of
alveolar septa area relative to the total area of a 20X field was
quantified while contouring and excluding bronchioles and large
vessels (see inset Table 3) and was performed in 20 fields of 20X, as
previously published [33]. Proliferation of tumor cells in lung nodules
was assessed by Ki-67 nuclear staining with anti-Ki-67 antibody (Ab)
(LifeSpan, Seattle, WA) followed by anti-rabbit biotinylated
secondary Ab (Vector Laboratories, Burlingame, CA); using an
avidin-biotin immunoperoxidase technique (Vector). The extent of
fibrosis was evaluated using Masson’s Trichrome stain (NovaUltra
Kit, IHCWORLD, Woodstock, MD) [31,33]. The lung vasculature
was visualized by fluorescent immunostaining, as previously shown inother studies [34–36]. Endothelial cells were identified with rat anti-
mouse CD31 Ab (Thermo Scientific, Fremont, CA) followed by
tetramethylrhodamine (TRITC)-labeled secondary goat anti-rat Ab
(Molecular Probes, Grand Island, NY). Pericytes were identified with
mouse anti-α-SMA (Sigma, St. Louis, MO) followed by Alexa Fluor
350-conjugated secondary goat anti-mouse Ab. The vessel basement
membrane was stained with rabbit anti-collagen type IV Ab
(Millipore, Billerica, MA) followed by Alexa Fluor 488-conjugated
secondary goat anti-rabbit Ab (Molecular Probes). All slides were
examined using a Nikon E-800 fluorescent microscope. Digital
images were taken separately with each fluorescent dye, including red
for endothelial cells, blue for pericytes and green for collagen, and
were then processed to create composite images with the three colors
using Image-ProPlus version 6.2 software.
Statistical analysis
Differences in mouse weight among the various treatments groups
were analyzed by two-tailed unpaired Student's t-test. For histological
data analysis, differences in the number and size of tumor nodules, and
Ki-67 positive tumor nuclei among the various treatments groups were
analyzed by two-tailed unpaired Student's t-test [31]. The Fisher’s
Exact test was used to assess the differences in proportion of damaged
vessels between treatment groups. No adjustments for multiple testing
were done. A p-value of 0.05 was considered statistically significant.
Results
Treatment of A549 lung tumor nodules with axitinib and
radiation: Safety of long-term treatment
To assess the long-term effect of axitinib combined with lung
irradiation, mice bearing established A549 lung tumor nodules were
treated with each modality or both combined as depicted in the
schedule presented in Table 1A. The need for prolonged axitinib
treatment after radiation and its safety were addressed by either
stopping axitinib after 5 weeks or continuing for 5 more weeks
(Table 1A). To assess the safety of the long-term treatment, mice were
weighed at various time points during the experiment, on days 25, 36,
46, 53, 67 and 79 (Table 1B). Compared to control untreated mice, a
mild decrease in mouse weight was observed following treatment with
radiation, axitinib and both combined of about 3-8% (Table 1B).
However, mice continued to gain weight in all treatment groups. No
statistical differences were obtained when the weight of treatment
groups were compared to control group or combined therapy was
compared to single modality (p N 0.1), suggesting a non-significant
minimal overall effect on the mouse weight. A mild increase in weight
was observed after axitinib was discontinued in axitinib treated mice
and radiation + axitinib treated mice. No obvious signs of toxicity
and no skin rashes indicative of bleeding were observed in mice
treated with radiation and axitinib, these mice were normally active
during the duration of the 3 months experiment. Histological
analysis of tissues from kidneys, heart and liver showed no alterations
in the vasculature of these organs by systemic treatment with axitinib
alone or combined with radiation, confirming the safety of the drug.
Mice were killed if they showed signs of distress including weight
loss, lethargy and tumors in limbs, due to cancer spread. Two control
mice with high lung tumor burden developed tumors in limbs and
metastatic hilar lymph nodes by day 77. Overall survival in this
experiment by day 88 was 50% for control mice, 100% for mice
treated with axitinib for 10 weeks, 75% for mice treated with axitinib
for 5 weeks, 88% in mice treated with radiation and 100% in mice
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obtained in the survival of mice at day 88 in the comparison of single
modality treatment groups versus combined modality treatment
groups (p = 0.72).
Enhanced therapeutic response in lung tumor nodules by
axitinib combined with high dose radiation
The therapeutic effect of axitinib and radiation of mice treated with
the schedule described in Table 1A was assessed in lung tissue sections
processed for H&E staining. In the control group, mice surviving upAxit + Rad (K)
Control (A)
T
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T
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Figure 1. H &E and Ki-67 staining of lung tissue sections from mi
processed for H& E staining and Ki-67 immunostaining. Lung section
hemorrhages (H) in the vicinity of invasive tumor nodules (panels A an
Following axitinib treatment, smaller tumor nodules with decreased ce
with focal areas of hemorrhages in lung tissue (panel E). Ki-67 sta
Radiation also resulted in small tumor nodules with decreased cellula
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tissue. Magnifications are 40x (bar size of 250 μm) for all Ki-67 pictuto 70-88 days had very large tumor nodules, which histologically
presented as large pleomorphic tumor cells with cytoplasmic vacuoles,
large nuclei and prominent nucleoli (Figure 1A), compatible with
poorly differentiated adenocarcinoma. Some of the large nodules were
hemorrhagic and necrotic (Figure 1B). The number of measurable
tumor nodules was estimated at 30-40 per lung, some were not
countable as they coalesced replacing large lung areas (Table 2). A
wide range of sizes was measured however most of them were very
large, and hemorrhagic with a mean area of 110x104 μm2 (Table 2).
These tumors showed a high proliferation index by Ki-67 stainingIF
Control (C)
Axitinib (F)
Radiation (I)
E 250 µm Ki-67
ce treated with axitinib and radiation. Lung tissue sections were
s from control mice showing large tumor nodules (T) and extensive
d B) with a high Ki-67 proliferation index in tumor nodules (panel C).
llularity and chronic inflammatory infiltrates (IF) were seen (panel D)
ining showed decreased proliferation in tumor nodules (panel F).
rity and heavy infiltration by chronic inflammatory cells (IF) (panel G,
e observed (panel H). Ki-67 staining showed decreased proliferation
diation, no tumor nodules were detectable but only isolated
f normal lung parenchyma were seen (panel K). Magnifications are
mphasize the effect of therapy both in tumor nodules and in lung
res (C,F,I) to show nuclei staining in the tumor cells.
Table 2. Quantitation and morphometric measurements of A549 lung tumor nodules from mice
treated with axitinib and radiation.
# Tumor
Nodules a
Nodule Area b Range c Ki-67+ Nuclei d Fibrosis e
mean ± SE×104 μm2 (x104μm2) mean ± SE
Control 30& 110 ± 24 13 – 503 111 ± 10.4 ±
Axitinib 21 10 ± 3 0.8 – 50 40 ± 1 ±
Radiation 34 8.4 ± 1.9 1.2 – 43 42 ± 9.7 + + +
Rad + Axit
(10w)
0 0 0 0 ±
Rad + Axit
(5w)
0 0 0 0 ±
a In H&E stained lung tissue sections, the tumor nodules were enumerated from 2 mice per treatment
group.&In control group, we are reporting 30 representative measurable tumors as some of the nodules were
invading large areas of septae and were not measurable. In the last treatment groups, axitinib was continued
for 10 weeks [Rad + Axit (10w)] or discontinued after 5 weeks [Rad + Axit (5w)].
b The nodule areawas estimated bymorphometricmeasurements of each tumor nodule and themean ± SEof
all nodules is reported.
c The range of nodule area is presented.
d The number of Ki-67 positive nuclei in tumor cells was enumerated in tumor nodules. The mean
positive nuclei per tumor nodule ± SE is reported.
e The extent of fibrosis was scaled from weak (±) to heavy (+ + +).
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The lung tissue showed a mix of normal lung alveoli and focal areas of
thick alveolar septa with hemorrhages which were observed in the
vicinity of tumor nodules (Figure 1B). Following treatment with
axitinib, several tumor nodules were still observed in the lung
(Figure 1D, Table 2), but these nodules were significantly smaller
than in control mice with a mean area of 10x104 μm2 (p = 0.001,
Table 2) and contained chronic inflammatory infiltrates (Figure 1D).
Focal areas of hemorrhages were observed in the lung tissue
(Figure 1E). A decrease in both cellularity and proliferative nuclei
were observed in the tumor nodules with a mean of Ki-67 positive
nuclei of 40 (Figure 1 F, Table 2, p b 0.01). Following radiation,
numerous tumor nodules were observed with a wide range in size,
however these nodules were significantly smaller than in control mice
with a mean area of 8.4x104 μm2 (p b 0.001, Table 2). Nodules
showed alterations in tumor cells and inflammatory infiltrates
(Figure 1G,H). Focal enlarged septa filled with chronic inflammatory
cells were seen, which may represent foci of tumor destruction
(Figure 1H). Akin to the effect of axitinib, radiation also caused a
decrease in cellularity and dividing nuclei in tumors with a mean of
Ki-67 positive nuclei of about 42 (Figure 1I, Table 2, p b 0.01). InTable 3. Quantitation of alveolar septa thickness in lungs from mice treated with axitinib and radiat
Ratio of Alveolar Septa Area/20X Field
Treatment Area
Ratio Range
Regular Septaa 0.3 - 0.49 Thick Septab 0.5
Proportion Percent Proportion
Tumor-Bearing Lungs
Control 8/20 40% 12/20
Axitinib 11/20 55% 9/20
Radiation 11/20 55% 9/20
Rad + Ax (10w) 14/20 70% 6/20
Rad + Ax (5w) 14/20 70% 6/20
Normal Lung 16/20 80% 4/20
Using software analysis of H&E slides, the ratio of alveolar septa area relative to the total area of 20X fiel
insetc). Data were stratified by using a ratio of 0.3-0.49 to define regular normal septaa,c and 0.50-0.65 to
representative mice are presented.contrast, no tumor nodules were detectable in lungs treated with
radiation and 10 weeks of axitinib but occasionally we observed
distinctive lymphohistiocytic nodules consisting of lymphocytes and
histiocytes with no detectable viable tumor cells (Figure 1 J; see
arrows). These nodules probably represent an anti-tumor inflamma-
tory response mediated by radiation and axitinib. The lung showed
large areas of normal parenchyma (Figure 1 K) and only focal areas of
thicker alveolar septae with inflammatory cells (Figure 1 J), compat-
ible with moderate interstitial pneumonia. Interestingly, a complete
anti-tumor response was also observed in mice treated with radiation
and 5 weeks of axitinib when lung tissues were evaluated 5 weeks
after discontinuation of axitinib (Table 2).
Effect of axitinib and/or radiation on lung alveolar septa and
evaluation of pneumonitis
To evaluate the effect of single and combined modalities on the
lung architecture and determine whether the treatment induced
pneumonitis at a late time point of 2 months after radiation and 5-10
weeks of treatment with axitinib, morphometric measurements of the
thickness of alveolar septa were conducted on H&E stained lung
tissue sections. The ratio of alveolar septa area relative to the total area
of 20X field was quantified while contouring and excluding bronchi,
bronchioles and large vessels (see inset Table 3). Data were stratified
by using an arbitrary cut-off ratio of 0.3-0.49 for normal septa and
0.50-0.65 to define thick septa regarded as reflective of pneumonitis
(see inset Table 3). Tumor-bearing lungs from control mice had a
high percentage of areas with thickened septa of 60% compared to
20% in lungs from mice not bearing tumors (normal lung, Table 3).
In multiple observations of slides from control tumors, these findings
were consistent and suggested that the presence of tumor nodules
causes pneumonitis, in agreement with the observations of focal areas
of thick alveolar septa with hemorrhages surrounding tumor nodules
(Figure 1B). The percent of thick septa areas in lungs treated with
axitinib or radiation was lower (45%) than in control tumor bearing
lungs that could be due to the much smaller tumor nodules in the
lung tissue (Table 3). Following axitinib combined with radiation, the
percent of thick septa was reduced to 30%, indicating a trend in
decreasing pneumonitis by combining both modalities (Table 3).
These quantitative data confirm our histology observations described
above (Figure 1).ion.
0 -0.65 Regular Septac
0.3 – 0.49
Thick Septad
0.50 – 0.65
Percent
60%
45%
45%
30%
30%
20%
d was quantified in 20 fields of 20X while contouring and excluding bronchioles and large vessels (see
define thick septab,d which is indicative of pneumonitis (see insetd). Data computed on lungs from 2
Rad (E)
Control (A)
Axit (C)
Control (B)
Axit (10w)+Rad (G)
Axit (5w)+Rad (I)
CD31 Collagen SMA
31 %
Axit (D)
Rad (F)
Axit (10w)+Rad (H)
Axit (5w)+Rad (J)
% Damaged
Vessels
36 %
55 %
36 %
28 %
V
V
V
V
V
V
V
V
V
V
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Figure 2. Fluorescent staining of vasculature in lung tissue sections from mice treated with axitinib and radiation. Lung tissue sections
were immunostained with fluorescent dyes, including red for endothelial cells (anti-CD31), blue for pericytes (anti-SMA) and green for
collagen (anti-collagen IV) as detailed in Materials & Methods. Representative images of large and small vessels (white arrows) of the lung
tissues are presented. (A,B) Vessels with integral basement membranes from control mice. (C,D) Vessels from axitinib-treated mice
showing disruptions or thickening in basement membrane collagen. (E,F) Vessels from radiation-treated mice showing thickening and
projections or interruptions in the continuity of basement membrane collagen. Vessels with integral basement membranes are shown
frommice treated with radiation and axitinib for up to 10 weeks (Axit + Rad in panels G,H) or in mice treated with radiation and axitinib for
5 weeks and then stopped (Axit (5w) + Rad in panels I,J). All 40X (bar size of 250 μm). The percentage of damaged vessels estimated in
20 fields of 40X, obtained from two mice per group, is reported in the third column.
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Lung tissue injury induced by radiotherapy leads to an
inflammatory process caused by radiation damage to capillary
endothelial cells and epithelial lung cells which results in pneumonitis
and fibrosis. To assess further the effect of axitinib on the vasculature
of the normal lung tissue, lung sections were stained with fluorescent
anti-CD31 antibody, anti-SMA and anti-collagen to stain endothelial
cells, pericytes and the vessel basement membranes, respectively. Thisfluorescent technique allows for visualization of vessel abnormalities
including interruptions in the continuity of basement membrane
collagen and/or thickening and projections in basement membrane,
as previously described [34,35] Representative images of large and
small vessels of the lung tissues are presented in Figure 2. We also
quantitated the percent of damaged vessels in 20 fields of 40X. Vessels
were considered damaged if the basement membrane was discontin-
uous (Figure 2C,F), or enlarged or had abnormal projections
Control
Axitinib
Radiation
Axit (10w)+Rad
Axit (5w) + Rad 
Control
Axitinib
Radiation
Axit (10w)+Rad
Axit (5w)+Rad 
250 µm
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with integral basement membranes (Figure 2A,B), with 31% showing
damage. Axitinib affected some of the vessels (about 36%) which
showed interruptions in the basement membrane (Figure 2C) while
other vessels had a full basement membrane (Figure 2D). Lungs
treated with radiation showed alterations in the basement membrane
of vessels including thickening and projections (Figure 2E) or
interruptions in the continuity of the collagen (Figure 2 F), which
occurred in 55% of the vessels, in agreement with our previous
reported studies [32]. In lungs treated with axitinib combined with
radiation a lower percentage of 36% vessels looked damaged while the
other vessels looked healthy (Figure 2G,H). Stopping axitinib for the
last 5 weeks of the experiment caused a decrease to 28% damaged
vessels (Figure 2I,J). No significant difference was observed between
the treatment groups but a trend in decreased damage in the lung
vasculature was seen in axitinib + radiation compared to radiation
alone (p = 0.13).
Extent of fibrosis in lung tissue treated with axitinib
and radiation
Lung pneumonitis induced by radiation is associated with
fibrosis, which is a late event in radiation-induced injury and the
result of an inflammatory process. The extent of fibrosis was
evaluated in lung tissue sections using the Masson’s Trichrome
stain. At a late time point of over two months after radiation, we
observed a dramatic increase in fibrosis in broncho-vascular bundles
visualized by the intense blue staining of collagen fibers surrounding
the vessels and bronchi (Figure 3, Table 2). These findings are
typical of radiation induced damage in lung tissue and have been
reproduced in several experiments in our laboratory. Increased
fibrosis was not seen following axitinib treatment either alone or
combined with radiation, the lung tissue was comparable to that of
control mice (Figure 3,Table 2).Figure 3. Lung fibrosis in mice treated with axitinib and radiation.
Lung tissue sections were stained with Masson’s Trichrome to
detect fibrosis. Bronchovascular bundles are shown in the lung
tissues from control mice andmice treated with axitinib or radiation
and both combined. Compared to thin collagen staining in lungs of
control tumor-bearing mice (control), irradiated lungs (radiation)
showed a drastic increase in fibrosis in broncho-vascular bundles,
which is visualized as intense blue staining of collagen fibers
surrounding the vessels and bronchioles. This finding was not
seen mice treated with axitinib or with radiation combined with
10 weeks axitinib (Axit + Rad) or 5 weeks axitinib (Axit (5w) + Rad).
All 40X (bar size of 250 μm).Discussion
In an attempt to improve the therapeutic ratio of radiotherapy for
inoperable Stage III locally advanced NSCLC, we have investigated
the use of the anti-angiogenic drug axitinib to target the tumor
vasculature given in conjunction with high dose irradiation of
tumor-bearing lungs in the A549 xenograft NSCLC murine pre-
clinical model.
In previous studies, we observed using DCE-MRI that pre-
treatment of tumors for 3-4 days with the anti-angiogenic drug
sunitinib regularizes the blood flow by trimming inefficient tumor
vessels and potentiates radiotherapy of kidney tumors [28,29].
Therefore, mice bearing established lung tumors were pre-treated
with axitinib for 4 days prior to lung irradiation, and then, axitinib
treatment was continued after radiation. The endpoints for evaluation
of the safety and therapeutic efficacy included assessing the duration
of axitinib treatment, its effect on mouse weight and health in
addition to the anti-tumor effect. Due to the anti-angiogenic property
of axitinib, emphasis was put on analyzing the systemic effect of the
drug on normal vasculature of the lungs and other organs to assess its
specificity at targeting tumors. We found that daily administration of
axitinib at 25 mg/kg for up to 3 months was well tolerated by the
mice with a non-significant slight decrease in mouse weight which
was reversed by discontinuation of axitinib. No other obvious signs of
toxicity were observed during monitoring of the mice following
axitinib given alone or in conjunction with lung irradiation.Histological analysis of tissues from kidney, heart and liver showed
that systemic treatment with axitinib did not cause disruption of
vasculature in these tissues in contrast to our previous observations
with sunitinib which did damage the vessels of kidneys [28]. These
data suggest that long-term treatment with axitinib is safe and are in
agreement with other pre-clinical studies in different tumor models
[18,20,21]. In clinical trials, axitinib has demonstrated a predictable
and manageable adverse event profile including diarrhea, hyperten-
sion, fatigue and nausea but no hematological or cardiovascular
toxicity were reported [37,38].
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using higher doses per fraction with the total treatment given in a
reduced number of fractions and less overall time, which is
potentially more effective and more convenient to patients [39,40].
A high dose of lung irradiation combined with prolonged axitinib
treatment was well tolerated and resulted in complete eradication of
lung tumors in a stark contrast to the extensive invasion of lung
tissue by large tumor nodules observed in control untreated mice.
This dramatic therapeutic efficacy was observed histologically in the
lungs of mice treated with axitinib for 10 weeks after radiation but
also in lungs of mice in which axitinib was discontinued after five
weeks, suggesting that this therapy does not require prolonged
treatment. When given as single modalities, axitinib or radiation
showed marked inhibition of tumor growth, decreasing tumor
cellularity and proliferative rate as assessed Ki-67 marker. Either
treatment also caused degenerative changes in the tumor cells and
infiltration by inflammatory cells. However, the combination of a
high single RT dose with axitinib was more effective than either
single modality confirming potentiation of RT efficacy by axitinib.
In long-term axitinib therapy after RT, we demonstrated a complete
destruction of lung tumor nodules in the orthotopic lung model.
Pre-clinical studies in subcutaneous prostate tumors demonstrated
enhanced tumor response by combining axitinib and fractionated
RT but these short term-studies of 2-3 weeks treatment
documented tumor growth delays [20,21]. Normalization of vessel
and blood flow did not seem to occur in these studies but they
showed destruction of tumor vasculature. Other studies in different
tumor models demonstrate a strong antigiogenic potential of
axitinib by pruning tumor vessels and inducing tumor cell death
observed by reduction of Ki-67 staining in agreement with the
effect observed in our lung model [17,18].
In NSCLC patients treated with radiotherapy, radiation pneumo-
nitis is an interstitial pulmonary inflammation that develops in up to
30% of patients [41,42]. It is caused by damage to lung parenchyma,
epithelial cells, vascular endothelial cells and stroma that involves
induction of pro-inflammatory cytokines and chemokines which
recruit inflammatory immune cells in the lung tissue [43,44]. This
acute early pneumonitis progresses to a chronic inflammation and
culminates in the later stage of lung fibrosis which is due to excessive
accumulation of collagen and other extracellular (ECM) components
[31,44,45]. These adverse events of radiotherapy affect patients’
breathing and their quality of life [41,42]. In the context of our
current studies, there is concern that radiation-induced injury to lung
tissue could be aggravated by vascular damage caused by anti-
angiogenic treatment. To address this issue, the architecture and
vasculature of lung tissues were investigated in the pre-clinical
NSCLC model. Pneumonitis was quantified by measuring the
thickness of alveolar septa [32]. In control tumor-bearing lungs, 60%
thickened septa was observed and associated with inflammation and
hemorrhages surrounding tumor nodules. This extensive pneumoni-
tis can be attributed to the effect of the presence of large tumor
nodules, at the late time points of 2-3 months and was also observed
in other independent studies [32]. Lungs treated with either modality
alone had both smaller tumor burden and less pneumonitis (45%
thickened septa), suggesting a relation between tumor burden and
pneumonitis. Pneumonitis was reduced to only 30% thickened septa
in lungs treated with both RT and axitinib compared to 20% found
in normal lungs. These findings taken together with the lack of
residual tumor nodules suggest that axitinib given in conjunctionwith radiation may mitigate interstitial pneumonia that is caused by
the presence of tumor and radiation.
The decreased pneumonitis observed by the combined therapy was
further supported by histological staining and evaluation of vascular
damage in the lung tissue. Pneumonitis has been associated with
vascular damage induced by radiation. In the current and previous
studies, we observed extensive hemorrhages induced by radiation
[31]. Vascular damage plays an important role in the development of
radiation-induced pulmonary toxicity and pulmonary hypertension.
Fluorescent staining of the basement membrane of vessels showed
that radiation caused alterations, interruptions and abnormal
projections in the basement membrane of 55% of lung vessels
whereas only 36% of vessels were altered in lungs treated with axitinib
alone or combined with radiation compared to 31% in control lungs.
Furthermore, stopping axitinib for the last 5 weeks of the experiment
caused a decrease to 28% damaged vessels. These data suggest that
axitinib causes moderate damage to normal lung vessels compared to
RT and this effect is reversed by discontinuation of the drug. It is
worth noting that axitinib did not exacerbate the damage caused by
radiation to the normal vasculature of the lung and therefore axitinib
may target more specifically tumor vessels.
Pneumonitis and fibrosis have been associated with lung injury
induced by radiation. Radiation-induced pneumonitis and fibrosis
were documented following single dose or fractionated radiation by
2-4 months after radiation in naïve mice and rats not-bearing lung
tumors [46,47]. Our recently published studies in the A549 tumor
model have shown that pneumonitis and fibrosis are detectable by
1 month after thoracic irradiation at a high dose of 10Gy or 12 Gy
[31,32]. As pneumonitis induced by radiation becomes chronic, later
time points of 2-4 months after lung irradiation showed both
increased pneumonitis and fibrosis in naïve mice [33]. These studies
suggest that radiation triggers a process of chronic inflammation
with concurrent progressive development of fibrosis. In the current
studies, at 2 months after radiation, prominent fibrosis was observed by
increased collagen fibers supporting the vessel walls and bronchial walls
which is in agreement with our previous studies. However, in lungs
treated with radiation and axitinib, a striking decrease in fibrosis in lung
tissue was observed. These data suggest that axitinib inhibits the
formation of fibrosis induced by radiation. These intriguing results
suggest a mechanism by which the anti-angiogenic drug could interfere
with the inflammatory process induced by radiation. In the process of
radiation-induced fibrogenesis, radiation activates the TGFβ signaling
pathway, which is involved in epithelial-to-mesenchymal transition
(EMT) leading to activation of fibroblasts and increased ECM and
collagen deposition [44]. Axitinib acting as a receptor tyrosine kinase
inhibitor could interfere with TGFβR and other growth factor receptors
signaling involved in fibrogenesis to inhibit the cascade of events leading
to fibroblast activation and fibrosis that is triggered by radiation [48].
Alternatively, axitinibmay act like sunitinib and inhibitmyeloid derived
suppressor cells which could be involved in the inflammatory response
caused by radiation [49]. Further studies are warranted to investigate
these mechanisms.
Overall, our data demonstrate that axitinib is a potent and safe drug to
use in conjunction with radiotherapy for lung cancer that could also act
as a radioprotector for lung tissue by reducing pneumonitis and fibrosis.
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